HRP20201831T1 - Optimizirani promoter rpe65 i kodirajuće sekvence - Google Patents
Optimizirani promoter rpe65 i kodirajuće sekvence Download PDFInfo
- Publication number
- HRP20201831T1 HRP20201831T1 HRP20201831TT HRP20201831T HRP20201831T1 HR P20201831 T1 HRP20201831 T1 HR P20201831T1 HR P20201831T T HRP20201831T T HR P20201831TT HR P20201831 T HRP20201831 T HR P20201831T HR P20201831 T1 HRP20201831 T1 HR P20201831T1
- Authority
- HR
- Croatia
- Prior art keywords
- sequence
- vector
- rpe
- seq
- specific promoter
- Prior art date
Links
- 239000013598 vector Substances 0.000 claims 18
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 238000010276 construction Methods 0.000 claims 5
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 4
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 2
- 208000032578 Inherited retinal disease Diseases 0.000 claims 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 210000000234 capsid Anatomy 0.000 claims 2
- 201000006321 fundus dystrophy Diseases 0.000 claims 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102000002717 c-Mer Tyrosine Kinase Human genes 0.000 claims 1
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000000736 oculocutaneous albinism type 1 Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01064—Retinoid isomerohydrolase (3.1.1.64)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Claims (12)
1. Konstrukcija vektora koja obuhvaća promotor specifičan za retinalni pigmentni epitel (RPE) i operativno povezanu sekvencu polinukleotida, naznačena time, što promotor specifičan za RPE obuhvaća:
(a) sekvencu susjednih nukleotida iz SEQ ID NO:1 koji dodjeljuju ekspresiju specifičnu za RPE na operativno povezanoj sekvenci polinukleotida, ili
(b) sekvencu koja sadrži sekvencu najmanje 90 %-tno identičnu sekvenci iz (a) i koja zadržava djelovanje promotora specifičnog za RPE,
i naznačena time, što operativno povezana sekvenca polinukleotida obuhvaća sekvencu SEQ ID NO: 4.
2. Konstrukcija vektora prema patentnom zahtjevu 1, naznačena time, što promotor specifičan za RPE obuhvaća:
(a) najviše 1300 susjednih nukleotida iz SEQ ID NO:1, ili
(b) sekvencu koja je najmanje 90 %-tno identična predmetnoj sekvenci od najviše 1300 susjednih nukleotida iz SEQ ID NO:1 i koja zadržava djelovanje promotora specifičnog za RPE.
3. Konstrukcija vektora prema patentnom zahtjevu 2, naznačena time, što promotor specifičan za RPE obuhvaća:
(a) najviše 800 susjednih nukleotida iz SEQ ID NO:1, ili
(b) sekvencu koja je najmanje 90 %-tno identična predmetnoj sekvenci od najviše 800 susjednih nukleotida iz SEQ ID NO: 1 i koja zadržava djelovanje promotora specifičnog za RPE, opcionalno
naznačena time, što promotor specifičan za RPE obuhvaća:
(a) sekvencu SEQ ID NO: 2 ili sekvencu nukleotida 12-761 iz SEQ ID NO: 2, ili
(b) sekvencu koja je najmanje 90 %-tno identična predmetnoj sekvenci SEQ ID NO: 2, ili koja sadrži nukleotide 12-761 iz SEQ ID NO:2, i koja zadržava djelovanje promotora specifičnog za RPE.
4. Konstrukcija vektora prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, što je predmetna sekvenca iz (a) ili (b) duga najmanje 500 nukleotida.
5. Vektor koji obuhvaća konstrukciju vektora prema bilo kojem patentnom zahtjevu od 1 do 4.
6. Vektor prema patentnom zahtjevu 5, naznačen time, što je predmetni vektor virusni vektor.
7. Vektor prema patentnom zahtjevu 6, naznačen time, što je vektor vektor adenoasociranog virusa (AAV) ili obuhvaća genom AAV-a ili njegov derivat, opcionalno
naznačen time, što derivat predstavlja kimerni derivat, rekombinirani derivat ili derivat modificiran kapsidom.
8. Vektor prema patentnom zahtjevu 7, naznačen time, što genom AAV-a potječe iz deriviranog serotipa ili izolata ili kladusa AAV-a, opcionalno
naznačen time, što genom AAV-a potječe iz serotipa 2 AAV-a (AAV2), serotipa 4 AAV-a (AAV4), serotipa 5 AAV (AAV5) ili serotipa 8 AAV-a (AAV8) i/ili naznačen time, što je kapsid dobiven iz AAV5 ili AAV8, poželjno
naznačen time, što je genom AAV-a dobiven iz AAV2, a kapsid je dobiven iz AAV5 ili AAV8.
9. Stanica domaćina koja sadrži vektor prema patentnom zahtjevu 5 ili proizvodi virusni vektor prema bilo kojem patentnom zahtjevu od 6 do 8, opcionalno naznačena time, što stanica domaćina jeste stanica HEK293 ili HEK293T.
10. Farmaceutski pripravak koji obuhvaća vektor prema bilo kojem patentnom zahtjevu od 5 do 8 i farmaceutski prihvatljivi nosač.
11. Vektor prema bilo kojem patentnom zahtjevu od 5 do 8 za primjenu u metodi sprječavanja ili liječenja retinalne distrofije.
12. Vektor za primjenu prema patentnom zahtjevu 11, naznačen time, što:
(a) retinalna distrofija je Leberova kongenitanla amauroza (LCA), starosna makularna degeneracija (AMD), očni albinizam okulokutanog tipa 1 ili tipa Nettleship-Falls ili deficijencija MERTK-a; i/ili
(b) liječenje ili prevencija postiže se primjenom vektora prema bilo kojem patentnom zahtjevu od 5 do 8 u pacijenta putem izravne retinalne, subretinalne ili intravitrealne injekcije, opcionalno
naznačen time, što se vektor primjenjuje izravno u retinalni, subretinalni prostor ili intravitrealni prostor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1502137.1A GB201502137D0 (en) | 2015-02-09 | 2015-02-09 | Treatment |
| PCT/GB2016/050289 WO2016128722A1 (en) | 2015-02-09 | 2016-02-08 | Optimized rpe65 promoter and coding sequences |
| EP16703850.4A EP3256169B1 (en) | 2015-02-09 | 2016-02-08 | Optimized rpe65 promoter and coding sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201831T1 true HRP20201831T1 (hr) | 2021-01-08 |
Family
ID=52746363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201831TT HRP20201831T1 (hr) | 2015-02-09 | 2020-11-17 | Optimizirani promoter rpe65 i kodirajuće sekvence |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10568973B2 (hr) |
| EP (2) | EP3769790A1 (hr) |
| JP (1) | JP6963503B2 (hr) |
| CN (1) | CN107429252B (hr) |
| AU (1) | AU2016217654B2 (hr) |
| BR (1) | BR112017017060A2 (hr) |
| CA (1) | CA2975850A1 (hr) |
| CY (1) | CY1123947T1 (hr) |
| DK (1) | DK3256169T3 (hr) |
| ES (1) | ES2830030T3 (hr) |
| GB (1) | GB201502137D0 (hr) |
| HK (1) | HK1248525A1 (hr) |
| HR (1) | HRP20201831T1 (hr) |
| HU (1) | HUE052407T2 (hr) |
| IL (2) | IL287142B2 (hr) |
| LT (1) | LT3256169T (hr) |
| MX (2) | MX2017010292A (hr) |
| PH (1) | PH12017501430A1 (hr) |
| PL (1) | PL3256169T3 (hr) |
| PT (1) | PT3256169T (hr) |
| RS (1) | RS61079B1 (hr) |
| SG (1) | SG11201706520UA (hr) |
| SI (1) | SI3256169T1 (hr) |
| WO (1) | WO2016128722A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201502137D0 (en) * | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| EP3448371A4 (en) * | 2016-04-28 | 2019-09-11 | Spark Therapeutics, Inc. | TESTING THE RELATIVE EFFECTIVENESS OF ISOMERHYDROLASES FOR THE CODING OF VIRAL VECTORS |
| RU2020121408A (ru) | 2017-11-30 | 2021-12-30 | Фридрих Мишер Инститьют Фор Байомедикал Рисерч | ПРОМОТОР SynPIII ДЛЯ СПЕЦИФИЧЕСКОЙ ЭКСПРЕССИИ ГЕНОВ В ПИГМЕНТНОМ ЭПИТЕЛИИ СЕТЧАТКИ |
| CN111118017B (zh) * | 2018-11-01 | 2023-10-03 | 上海朗昇生物科技有限公司 | 治疗Leber先天性黑蒙症的载体及其应用 |
| GB202002202D0 (en) | 2020-02-18 | 2020-04-01 | Ucl Business Plc | Gene therapy |
| AU2021314400A1 (en) * | 2020-07-21 | 2023-03-23 | Frontera Therapeutics, Inc. | Compositions and methods for the treatment of ocular diseases |
| CN111826378B (zh) * | 2020-08-05 | 2022-05-27 | 武汉纽福斯生物科技有限公司 | 一种编码人受体酪氨酸激酶Mer的核苷酸序列及其应用 |
| CN112522292B (zh) * | 2020-10-29 | 2023-05-02 | 南京启真基因工程有限公司 | 一种用于构建先天性黑蒙症克隆猪核供体细胞的CRISPR/Cas9系统及其应用 |
| AU2022340595A1 (en) * | 2021-09-06 | 2024-04-18 | Huidagene Therapeutics (Singapore) Pte. Ltd. | Treatment of rpe65-associated eye diseases and disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1788084A4 (en) | 2004-08-06 | 2007-11-07 | Chemo Sero Therapeut Res Inst | YEAST PROMOTER |
| US7740836B2 (en) | 2006-05-03 | 2010-06-22 | Fondazione Telethon | Methods and compositions for recovering or improving visual function |
| US20100081707A1 (en) * | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| HUE044089T2 (hu) | 2011-07-18 | 2019-09-30 | Inst Res Biomedicine | Neutralizáló anti-influenza A antitestek és alkalmazásaik |
| US9163259B2 (en) * | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| GB201502137D0 (en) * | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| GB202002073D0 (en) * | 2020-02-14 | 2020-04-01 | Ucl Business Ltd | Horizontal cells |
| GB202002202D0 (en) * | 2020-02-18 | 2020-04-01 | Ucl Business Plc | Gene therapy |
-
2015
- 2015-02-09 GB GBGB1502137.1A patent/GB201502137D0/en not_active Ceased
-
2016
- 2016-02-08 SI SI201630984T patent/SI3256169T1/sl unknown
- 2016-02-08 DK DK16703850.4T patent/DK3256169T3/da active
- 2016-02-08 PL PL16703850T patent/PL3256169T3/pl unknown
- 2016-02-08 CN CN201680020425.6A patent/CN107429252B/zh active Active
- 2016-02-08 HU HUE16703850A patent/HUE052407T2/hu unknown
- 2016-02-08 IL IL287142A patent/IL287142B2/en unknown
- 2016-02-08 EP EP20193488.2A patent/EP3769790A1/en active Pending
- 2016-02-08 EP EP16703850.4A patent/EP3256169B1/en active Active
- 2016-02-08 CA CA2975850A patent/CA2975850A1/en active Pending
- 2016-02-08 WO PCT/GB2016/050289 patent/WO2016128722A1/en active Application Filing
- 2016-02-08 ES ES16703850T patent/ES2830030T3/es active Active
- 2016-02-08 AU AU2016217654A patent/AU2016217654B2/en active Active
- 2016-02-08 MX MX2017010292A patent/MX2017010292A/es unknown
- 2016-02-08 US US15/549,549 patent/US10568973B2/en active Active
- 2016-02-08 JP JP2017541749A patent/JP6963503B2/ja active Active
- 2016-02-08 LT LTEP16703850.4T patent/LT3256169T/lt unknown
- 2016-02-08 RS RS20201400A patent/RS61079B1/sr unknown
- 2016-02-08 SG SG11201706520UA patent/SG11201706520UA/en unknown
- 2016-02-08 BR BR112017017060-4A patent/BR112017017060A2/pt active Search and Examination
- 2016-02-08 PT PT167038504T patent/PT3256169T/pt unknown
-
2017
- 2017-08-08 IL IL253915A patent/IL253915B/en unknown
- 2017-08-09 PH PH12017501430A patent/PH12017501430A1/en unknown
- 2017-08-09 MX MX2021006762A patent/MX2021006762A/es unknown
-
2018
- 2018-06-20 HK HK18107902.2A patent/HK1248525A1/zh unknown
-
2020
- 2020-02-20 US US16/796,439 patent/US11969478B2/en active Active
- 2020-11-17 HR HRP20201831TT patent/HRP20201831T1/hr unknown
- 2020-11-26 CY CY20201101129T patent/CY1123947T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201831T1 (hr) | Optimizirani promoter rpe65 i kodirajuće sekvence | |
| JP7390693B2 (ja) | 抗体回避性ウイルスベクターのための方法および組成物 | |
| FI3684423T3 (fi) | Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä | |
| JP6042825B2 (ja) | 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法 | |
| HRP20192141T1 (hr) | Genska terapija za retinitis pigmentosa | |
| HRP20201544T1 (hr) | Pripravci korisni u liječenju nedostatka ornitinske transkarbamilaze (otc) | |
| PH12020550706A1 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
| JP2021073188A (ja) | 標的化遺伝子移入のための方法および組成物 | |
| JP2017518271A5 (hr) | ||
| HRP20201324T1 (hr) | Vektori aav koji sadrže faktor viii koji kodira gen | |
| JP2014512171A5 (hr) | ||
| RU2013151885A (ru) | Вирионы аденоассоциированного вируса с вариантным капсидом и способы их использования | |
| JP2018510620A5 (hr) | ||
| IL292999A (en) | Preparations and methods for the treatment of amyotrophic lateral sclerosis | |
| EP3728568A1 (en) | Methods and compositions for delivery of viral vectors across the blood-brain barrier | |
| JP2022141670A5 (hr) | ||
| HRP20230522T1 (hr) | Isporuka adeno-povezanog virusnog vektora mišićno specifičnog mikrodistrofina za liječenje mišićne distrofije | |
| Wagner et al. | Synthetic biology: emerging concepts to design and advance adeno‐associated viral vectors for gene therapy | |
| CN110770346A (zh) | 多倍体腺相关病毒载体及其制备和使用方法 | |
| JP2015523379A5 (hr) | ||
| JP2017509632A5 (hr) | ||
| RU2018132517A (ru) | Aav-idua вектор для лечения ассоциированной с mps i слепоты | |
| MX2022014258A (es) | Composiciones para la reducción específica de un fármaco de la expresión de transgén. | |
| JP2017529395A5 (hr) | ||
| CO2021011040A2 (es) | Virus adenoasociado recombinante para el tratamiento de la neurodegeneración de inicio en adultos asociada a grn |